Theriva Biologics Responds to Unusual Market Activity, Attributes No Material Business Development or Reason for Trading Action

Theriva Biologics, a clinical-stage company developing therapeutics for cancer and related diseases, has announced unusual trading activity in its common stock on the NYSE American. The company has made inquiries and does not believe corrective actions are necessary. The unusual market action may be attributed to the company's recent announcement of expanded data from its VIRAGE trial investigating VCN-01 at ESMO 2025 Annual Congress.